Bavarian Nordic A/S
CSE:BAVA
Intrinsic Value
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. [ Read More ]
The intrinsic value of one BAVA stock under the Base Case scenario is 224.44 DKK. Compared to the current market price of 162.9 DKK, Bavarian Nordic A/S is Undervalued by 27%.
Valuation Backtest
Bavarian Nordic A/S
Run backtest to discover the historical profit from buying and selling BAVA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bavarian Nordic A/S
Current Assets | 5.4B |
Cash & Short-Term Investments | 1.9B |
Receivables | 1.8B |
Other Current Assets | 1.7B |
Non-Current Assets | 9B |
PP&E | 2.5B |
Intangibles | 6.5B |
Other Non-Current Assets | 15.7m |
Current Liabilities | 2.8B |
Accounts Payable | 954.1m |
Accrued Liabilities | 419.8m |
Other Current Liabilities | 1.4B |
Non-Current Liabilities | 1.2B |
Long-Term Debt | 98.8m |
Other Non-Current Liabilities | 1.1B |
Earnings Waterfall
Bavarian Nordic A/S
Revenue
|
7.1B
DKK
|
Cost of Revenue
|
-2.5B
DKK
|
Gross Profit
|
4.6B
DKK
|
Operating Expenses
|
-2.5B
DKK
|
Operating Income
|
2.1B
DKK
|
Other Expenses
|
-649m
DKK
|
Net Income
|
1.5B
DKK
|
Free Cash Flow Analysis
Bavarian Nordic A/S
BAVA Profitability Score
Profitability Due Diligence
Bavarian Nordic A/S's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Bavarian Nordic A/S's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
BAVA Solvency Score
Solvency Due Diligence
Bavarian Nordic A/S's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Score
Bavarian Nordic A/S's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BAVA Price Targets Summary
Bavarian Nordic A/S
According to Wall Street analysts, the average 1-year price target for BAVA is 272.63 DKK with a low forecast of 177.76 DKK and a high forecast of 347.55 DKK.
Shareholder Return
BAVA Price
Bavarian Nordic A/S
Average Annual Return | 22.9% |
Standard Deviation of Annual Returns | 27.01% |
Max Drawdown | -68% |
Market Capitalization | 12.7B DKK |
Shares Outstanding | 77 944 140 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The firm is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one BAVA stock under the Base Case scenario is 224.44 DKK.
Compared to the current market price of 162.9 DKK, Bavarian Nordic A/S is Undervalued by 27%.